MYC and colorectal carcinoma: Using a CRISPR loss-of-function screen, McCleland et al. identified a member of the bromodomain and extra terminal (BET) protein family (BRD4) as a key epigenetic regulator, which interacts with lncRNA CCAT1 for BET-mediated c-MYC regulation in CIMP+ CRC; suggesting CCAT1 as a predictor of sensitivity to BET inhibitor drug JQ1 [47].